Driving paradigm change in precision medicine in NSCLC
In this exclusive workshop co-sponsored with Takeda Pharmaceuticals, we are excited to host oncologist Dr. Jyoti D. Patel and pathologist Dr. Amir Behdad from Northwestern Medicine.
Dr. Patel and Dr. Behdad will review the rapidly evolving biomarker landscape and latest clinical research data in non-small cell lung cancer (NSCLC), with a focus on several emerging new biomarkers, such as EGFR exon 20 insertions. They will highlight how the potential paradigm change in NSCLC may impact their practice and the importance of NGS and turnaround time (TAT) to enable best treatment decisions in the future. Dr. Patel and Dr. Behdad will also share best practices developed through their experience of working together as a care team and the value of tumor boards and in-house NGS.
Co-sponsored with Takeda Pharmaceuticals
Dr. Jyoti D. Patel
Dr. Amir Behdad